Deal

ABBOTT LABORATORIES acquires Guidant's vascular intervention and endovascular businesses

April 2006 carve-out ready

Snapshot

ABBOTT LABORATORIES acquired Guidant's vascular intervention and endovascular businesses for approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant) in April 2006. The transaction was structured as combination (cash plus a loan and milestone payments). Guidant's vascular intervention and endovascular businesses is a Santa Clara, California, USA-based Medical devices — vascular intervention business.

Acquirer
ABBOTT LABORATORIES
Target
Guidant's vascular intervention and endovascular businesses
Value
approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant)
Date
April 2006
Type
carve-out
Status
ready
01 Scorecard

The deal at a glance

Private-market deal
ABBOTT LABORATORIES acquires Guidant's vascular intervention and endovascular businesses
Deal value
approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant)
Sector
Medical devices — vascular intervention
Date
April 2006
VectorShift
Made on VectorShift

About this deal

ABBOTT LABORATORIES acquired Guidant's vascular intervention and endovascular businesses for approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant), a transaction completed in April 2006, structured as combination (cash plus a loan and milestone payments). The deal was a carve-out.

Guidant's vascular intervention and endovascular businesses operates in Medical devices — vascular intervention, is based in Santa Clara, California, USA. Guidant's vascular intervention and endovascular solutions businesses, including coronary and peripheral stent and angioplasty product lines, acquired from Boston Scientific as a condition of Boston Scientific's acquisition of Guidant.

Combination of Abbott's and Guidant's vascular organizations creates a stronger vascular business and gives Abbott a leading position in vascular intervention.

Established Abbott as a major player in the global vascular intervention market with a drug-eluting stent pipeline. Became Abbott Vascular

Advisors not disclosed

No advisory firms have been disclosed for this transaction.

Sources Press releaseSEC filing Last updated

See how VectorShift works for your firm

Request Demo